LCAHA

• CAT Number: I030581
• CAS Number: 117094-40-3
• Molecular Formula: C24H41NO3
• Molecular Weight: 391.59
• Purity: ≥95%
• Synonyms: (4R)-N-hydroxy-4-[(3R,5R,8R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanamide
• InChI: InChI=1S/C24H41NO3/c1-15(4-9-22(27)25-28)19-7-8-20-18-6-5-16-14-17(26)10-12-23(16,2)21(18)11-13-24(19,20)3/h15-21,26,28H,4-14H2,1-3H3,(H,25,27)/t15-,16-,17-,18+,19-,20+,21+,23+,24-/m1/s1
• InChIKey: WZXAGWREMCSWMF-HVATVPOCSA-N
• SMILES: CC(CCC(=O)NO)C1CCC2C1(CCC3C2CCC4C3(CCC(C4)O)C)C

LCAHA (Cat No.: I030581) is a synthetic derivative of lithocholic acid, a secondary bile acid, developed to explore bile acid signaling and its therapeutic potential. LCAHA has been studied for its ability to modulate nuclear receptors, particularly the farnesoid X receptor (FXR) and vitamin D receptor (VDR), influencing pathways linked to lipid metabolism, inflammation, and cancer biology. Its modified structure enhances stability and receptor selectivity compared to natural bile acids, making LCAHA a valuable probe in metabolic and pharmacological research.

Reference

[1]. Katarzyna Magiera, et al. Lithocholic Acid Hydroxyamide Destabilizes Cyclin D1 and Induces G 0/G1 Arrest by Inhibiting Deubiquitinase USP2a. Cell Chem Biol. 2017 Apr 20;24(4):458-470.e18.
[Content Brief]